Apogee Therapeutics (APGE) Preferred Stock Liabilities (2022 - 2023)
Apogee Therapeutics (APGE) reported Preferred Stock Liabilities of $148.5 million for Q3 2023, up 1717.35% year-over-year from $8.2 million in Q3 2022, and little changed quarter-over-quarter from $148.5 million in Q2 2023.
Apogee Therapeutics (APGE) Preferred Stock Liabilities (2022 - 2023) Analysis & Trends
Apogee Therapeutics (APGE) has 2 years of Preferred Stock Liabilities data on file, last reported at $148.5 million in Q3 2023.
- Preferred Stock Liabilities for Q3 2023 came in at $148.5 million, up 1717.35% year-over-year; the trailing twelve-month figure through Sep 2023 was $148.5 million (up 1717.35% YoY), and the FY2022 annual result was $29.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities was little changed at $148.5 million in Q3 2023 per APGE's latest filing, from $148.5 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $148.5 million in Q2 2023 and troughed at $3.8 million in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Apogee Therapeutics | 6.29 Bn | 5.23 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 148.50 Mn |
| Jun 30, 2023 | 148.50 Mn |
| Mar 31, 2023 | 28.97 Mn |
| Dec 31, 2022 | 28.97 Mn |
| Sep 30, 2022 | 8.17 Mn |
| Jun 30, 2022 | 3.77 Mn |